# A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis

> **NCT03334435** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 1645 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Baricitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03334435
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-28
- **Primary completion:** 2020-09-21
- **Final completion:** 2023-07-12
- **Target enrollment:** 1645 (ACTUAL)
- **Last updated:** 2024-09-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03334435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03334435, "A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03334435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*